Back to Results
First PageMeta Content
Peptides / Hereditary angioedema / Angioedema / C1-inhibitor / Icatibant / Ecallantide / Danazol / Preventive medicine / CSL Behring / Medicine / Health / Complement deficiency


Final protocol to guide the assessment of C1 esterase inhibitor for hereditary angioedema National Blood Agreement Schedule 4
Add to Reading List

Document Date: 2015-03-04 23:43:06

Open Document

File Size: 1,08 MB

Share Result on Facebook

Company

ViroPharma / Cedarglen Investments / MCA / C1 / Jurisdictional Blood Committee Working Group / CSL Behring / JBC Working Group / Pharming Group / Australia 8 Management / /

Country

Germany / Netherlands / United States / Australia / United Kingdom / /

Currency

USD / /

Event

M&A / Debt Financing / FDA Phase / /

Holiday

Commonwealth Day / /

IndustryTerm

peripheral site / treatment of the underlying disease / blood products / health services / management algorithm / reconstitution device / Final protocol / healthcare / pharmaceutical / factor products / medicinal products / manufacturing process / proposed clinical management algorithm / proposed management algorithm / clinical management algorithm / blood product / /

MedicalCondition

greater disease / non-itchy rash / comprehensive hereditary angioedema prophylaxis program / similar bleeding disorders / lymphoma / angioedema attacks Routine prevention / haemophilia / liver adenoma / HAE / carcinoma / C1-esterase inhibitor deficiency / severe abdominal pain / hereditary angioedema / acute angioedema attacks / infections / late-onset acquired angioedema / angioedema attack / hypotension / Abdominal pain / disease / hereditary angioedema National Blood Agreement Schedule / autosomal dominant disorder / pain / vomiting / angioedema attacks Pre-procedure prevention / acute angioedema attack pre-procedural prophylaxis routine prophylaxis self-admin / urticaria / angioedema / angioedema attacks / angioedema attacks Treatment / less severe angioedema / infection / depression / /

MedicalTreatment

intravenous infusions / oral therapies / emergency treatment / surgery / oral therapy / head surgery / immunoglobulin therapies / dental surgery / neck surgery / drug therapy / /

Organization

Approved Pathology Authority / I.V. administration / Current C1-INH administration / Therapeutic Goods Administration / Jurisdictional Blood Committee / Commonwealth government / Streamlined Authority / World Allergy Association / National Blood Authority / Australasian Society of Clinical Immunology and Allergy / FDA / Home/community administration / Department of Health / Medical Services Advisory Committee / /

Person

Comparator Icatibant / Berinert Self / /

Position

Commonwealth Minister / mediator / community health worker / General / prescribing physician / King / general physician / respiratory physician / specialist / nurse / Source General Schedule General Schedule General / community nurse / treating physician / Major / Government Health Minister / nurse / or self/home-administered / /

Product

ICATIBANT Injection / danazol / I.V. injection / Cyklokapron / INH / HAE / US / Cinryze / tranexamic / /

ProvinceOrState

South Australia / /

Region

South Australia / /

SportsEvent

NBA / the NBA / /

Technology

6 Clinical management algorithm / 7 Clinical management algorithm / management algorithm / ASCIA algorithm / ASCIA clinical management algorithm / proposed management algorithm / proposed clinical management algorithm / ASCIA management algorithm / clinical management algorithm / /

URL

www.allergy.org.au / /

SocialTag